In July 2025, the FDA approved Longeveron’s Investigational New Drug (IND) application for its stem cell therapy laromestrocel as a potential treatment for pediatric dilated cardiomyopathy (DCM). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback